Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M |
| Total Depreciation and Amortization | 3.20M | 3.19M | 3.16M | 3.14M | 3.13M |
| Total Amortization of Deferred Charges | 866.00K | 843.00K | 820.00K | 844.00K | 824.00K |
| Total Other Non-Cash Items | 5.27M | 7.64M | 5.01M | 4.44M | 3.61M |
| Change in Net Operating Assets | -373.00K | 6.14M | -6.88M | -9.24M | -474.00K |
| Cash from Operations | 20.04M | 18.43M | 182.00K | -10.03M | 1.98M |
| Capital Expenditure | -333.00K | -71.00K | -279.00K | -13.00K | -220.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 10.24M |
| Cash from Investing | -333.00K | -71.00K | -279.00K | -13.00K | 10.02M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.27M | 14.33M | 1.80M | 4.86M | 564.00K |
| Repurchase of Common Stock | -1.54M | -478.00K | -860.00K | -8.00M | -166.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | -266.00K | 13.85M | 942.00K | -3.14M | 398.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.44M | 32.21M | 845.00K | -13.18M | 12.39M |